Business Context and Reporting Period
Company: Techne Corporation (now BIO-TECHNE Corp)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended March 31, 1995
Business Overview: The Company operates through two subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) in Minneapolis and R&D Systems Europe Ltd. in Abingdon, England. Operations are divided into Biotechnology (cytokines, antibodies, assay kits) and Hematology (blood controls and calibrators) divisions.
Key Financial Metrics
| Metric | Quarter Ended 3/31/95 | Nine Months Ended 3/31/95 | Nine Months Ended 3/31/94 |
|---|---|---|---|
| Sales | $12,576,041 | $34,897,468 | $29,431,032 |
| Gross Margin | $7,572,070 (60.2%) | $20,992,124 (60.2%) | $16,759,482 (56.9%) |
| Net Earnings | $1,783,804 | $4,598,113 | $3,385,765 |
| Earnings Per Share (Diluted) | $0.19 | $0.48 | $0.36 |
| Cash & Equivalents | $5,227,011 | N/A (Balance Sheet Item) | |
| Short-term Investments | $9,254,368 | N/A (Balance Sheet Item) | |
| Total Current Assets | $25,675,895 | N/A (Balance Sheet Item) | |
| Total Current Liabilities | $3,441,596 | N/A (Balance Sheet Item) | |
| Long-term Debt | $0 | N/A (Balance Sheet Item) | |
| Net Cash from Operations (9mo) | $4,773,868 | $4,541,911 |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 15% for the quarter and 19% for the nine-month period compared to the prior year. Growth was driven by a 25% increase in R&D Europe sales and a 10% increase in R&D Systems sales.
- Product Drivers: Approximately 54% of the quarterly sales increase was attributed to R&D Systems' immunoassay (Quantikine) kits. Sales of these kits reached $4.9 million for the quarter.
- Margin Expansion: Gross margins improved to 60.2% for both the quarter and nine-month period (up from 58.5% and 56.9% respectively). This was largely due to favorable exchange rate variances benefiting R&D Europe and improved margins in the Biotechnology Division.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 17% for the quarter and 20% for the nine months, driven by added staff, consulting fees, and marketing costs. R&D expenses increased 22% for the quarter and 32% for the nine months due to new product development.
- Debt Reduction: The Company paid off its current portion of long-term debt ($29,875) during the period, resulting in zero long-term debt on the balance sheet as of March 31, 1995.
Guidance, Outlook, and Risks
- Seasonality: Management expects fourth-quarter sales to be slightly lower than the third quarter due to the annual slowdown in European sales during summer months.
- Strategic Investments: The Company made a $1,000,000 prepayment to Cistron Biotechnology, Inc. for a sublicense to sell interleukin-1 beta products. Additionally, a new R&D agreement involves quarterly payments of $100,000 starting July 1, 1995.
- Capital Allocation: The Company plans to purchase approximately $400,000 of its own stock for the Stock Bonus Plan in the fourth quarter and intends to purchase up to $5,000,000 of common stock over the next twelve months, subject to market conditions.
- Liquidity: The Company holds $14.5 million in cash and short-term investments and maintains a $750,000 unsecured line of credit. Management believes current funds are sufficient for future expansion and working capital needs.
- Risks: The Hematology Division saw a slight decrease in sales for the nine-month period due to competitive factors. The Company relies heavily on the Biotechnology Division and R&D Europe for growth.
Investor Verification Checklist
- Revenue Concentration: Verify the continued growth trajectory of the Quantikine immunoassay kits, which drove over half of the recent sales increase.
- Foreign Exchange Impact: Assess the sustainability of the gross margin improvement, which was partially driven by favorable exchange rates for R&D Europe.
- Share Repurchase Plan: Monitor the execution of the planned $5 million share repurchase program and its impact on outstanding share count and EPS.
- License Agreement Terms: Review the specifics of the Cistron Biotechnology agreement and the amortization schedule for the $1 million prepayment.
- Hematology Division Performance: Investigate the competitive pressures causing the decline in the Hematology Division's sales and earnings.